Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Dapoxetine/Tadalafil in PE and ED
NCT03177746Phase 4Unknown
- Sponsor
- Neutec Group
- Start
- Dec 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapoxetine and tadalafil in premature ejaculation (PE) and erectile dysfunction (ED), sponsored by Neutec Group. Primary endpoint: Evaluation of safety of study drug at 4 weeks. Status: unknown.
02
Drugs
dapoxetinetadalafil
03
Conditions
premature ejaculation (PE)erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT03177746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03177746.